Dr. Willmott on FDA Approval of Maintenance Olaparib in Ovarian Cancer

Lyndsay J. Willmott, MD, a gynecologic oncologist with Arizona Oncology, discusses the FDA approval of olaparib (Lynparza) in the maintenance setting for relapsed patients with platinum-sensitive ovarian cancer.

Lyndsay J. Willmott, MD, a gynecologic oncologist with Arizona Oncology, discusses the FDA approval of olaparib (Lynparza) in the maintenance setting for relapsed patients with platinum-sensitive ovarian cancer.

Related Content:

OncLive TVOvarian Cancer
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management
Dr Moore on AEs Associated With ADC Treatment in Gynecologic Cancers